• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Can Commun Dis Rep . Rapid review of multisystem inflammatory syndrome in paediatrics: What we know one year later

tetano

Editor, Senior Moderator
Can Commun Dis Rep


. 2021 Nov 10;47(11):466-472.
doi: 10.14745/ccdr.v47i11a04.
Rapid review of multisystem inflammatory syndrome in paediatrics: What we know one year later


Megan Striha[SUP] 1 [/SUP], Rojiemiahd Edjoc[SUP] 1 [/SUP], Natalie Bresee[SUP] 2 [/SUP], Nicole Atchessi[SUP] 1 [/SUP], Lisa Waddell[SUP] 3 [/SUP], Terri-Lyn Bennett[SUP] 4 [/SUP], Emily Thompson[SUP] 1 [/SUP], Maryem El Jaouhari[SUP] 1 [/SUP], Samuel Bonti-Ankomah[SUP] 1 [/SUP]



Affiliations

Abstract

Background: : Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19) is an emerging condition that was first identified in paediatrics at the onset of the COVID-19 pandemic. The condition is also known as pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (PIMS-TS or PIMS), and multiple definitions have been established for this condition that share overlapping features with Kawasaki Disease and toxic shock syndrome.
Methods: : A review was conducted to identify literature describing the epidemiology of MIS-C, published up until March 9, 2021. A database established at the Public Health Agency of Canada with COVID-19 literature was searched for articles referencing MIS-C, PIMS or Kawasaki Disease in relation to COVID-19.
Results: : A total of 195 out of 988 articles were included in the review. The median age of MIS-C patients was between seven and 10 years of age, although children of all ages (and adults) can be affected. Multisystem inflammatory syndrome in children disproportionately affected males (58% patients), and Black and Hispanic children seem to be at an elevated risk for developing MIS-C. Roughly 62% of MIS-C patients required admission to an intensive care unit, with one in five patients requiring mechanical ventilation. Between 0% and 2% of MIS-C patients died, depending on the population and available interventions.
Conclusion: : Multisystem inflammatory syndrome in children can affect children of all ages. A significant proportion of patients required intensive care unit and mechanical ventilation and 0%-2% of cases resulted in fatalities. More evidence is needed on the role of race, ethnicity and comorbidities in the development of MIS-C.

Keywords: COVID-19; Keywords: multisystem inflammatory syndrome in children; MIS-C; PIMS; PIMS-TS; pediatric multisystem inflammatory syndrome.
 
Back
Top Bottom